- Bora Pharmaceuticals and Corealis Pharma have formed a strategic alliance to offer end-to-end oral solid dose (OSD) development and manufacturing services.
- The collaboration aims to simplify early-phase to commercial-scale drug development through integrated CDMO support.
Bora Pharmaceuticals Co., Ltd. has entered a strategic alliance with Corealis Pharma Inc. to provide a unified pathway for oral solid dose (OSD) drug development and manufacturing. The companies said the partnership is intended to simplify outsourcing and create a scalable route from early formulation work through to commercial production.
The alliance brings together Bora’s global commercial manufacturing infrastructure and Corealis’ expertise in early-phase formulation and clinical-scale development. According to the announcement, the collaboration responds to increasing complexity in drug manufacturing and the demand for specialised partners across the development lifecycle.
Both organisations will offer integrated project management and aligned quality systems, aiming to reduce outsourcing risks and provide biotech and pharmaceutical companies with a single continuum from discovery to commercial launch. The agreement outlines how the alliance intends to support innovators seeking a smoother transition between clinical and commercial manufacturing stages.
“This collaboration is all about bridging capability and culture. This relationship combines Bora’s scale-up capabilities with Corealis’ early-phase strengths.”
J.D. Mowery, President of Bora’s CDMO division
David Leroux-Petersen, CEO of Corealis Pharma, said the alliance is designed to address challenges faced by emerging biotechs, offering a “clear, fast, seamless, simple path to phase III manufacturing and commercial launch.”
